GSE120210 GSE120214 TBXT brachyury inhibition 1 v 5 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE120210_GSE120214_TBXT_brachyury inhibition_1_v_5_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE120210_GSE120214_TBXT_brachyury inhibition_1_v_5_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE120210_GSE120214_TBXT_brachyury inhibition_1_v_5_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE120210_GSE120214_TBXT_brachyury inhibition_1_v_5_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H19 imprinted maternally expressed transcript

Gene

POU class 3 homeobox 3

Gene

OIP5 antisense RNA 1

Gene

general transcription factor IIi pseudogene 4

Gene

BAIAP2 divergent transcript

Gene

MT-CO2 pseudogene 12

Gene

MT-ATP6 pseudogene 1

Gene

USP2 antisense RNA 1

Gene

ILF3 divergent transcript

Gene

ZNF496 divergent transcript

  • Gene

    H19 imprinted maternally expressed transcript


  • Gene

    POU class 3 homeobox 3


  • Gene

    OIP5 antisense RNA 1


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    BAIAP2 divergent transcript


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    MT-ATP6 pseudogene 1


  • Gene

    USP2 antisense RNA 1


  • Gene

    ILF3 divergent transcript


  • Gene

    ZNF496 divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.